查找临床试验
已按「血管炎」检索，对应国际通用词 vasculitis
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:24，每 5 分钟自动同步Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
China
年龄 18 Years – 70 Years
Changhai Hospital
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
China
年龄 18 Years – 65 Years
Nanjing University School of Medicine
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
China
年龄 18 Years – 75 Years
Ganzhou Hemay Pharmaceutical Co., Ltd
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
China
年龄 18 Years – 65 Years
Second Affiliated Hospital, Zhejiang University, School of Medicine
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Tongji Hospital
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Argentina、Australia、Brazil、Canada、China 等 12 国
年龄 18 Years – 80 Years
Alexion Pharmaceuticals, Inc.
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
China
年龄 18 Years – 65 Years
Therorna
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
China
年龄 18 Years – 90 Years
Essen Biotech
Baricitinib in the Treatment of Intestinal Behçet's Syndrome
China
年龄 18 Years – 65 Years
Peking Union Medical College Hospital
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
China
年龄 3 Years – 不限
The Children's Hospital of Zhejiang University School of Medicine
Generative AI Impact on Rheumatoid Arthritis Complications Diagnosis
China
年龄 不限 – 不限
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
United States、Australia、Austria、Bulgaria、Canada 等 12 国
年龄 18 Years – 85 Years
Chugai Pharmaceutical